MDS
Clinical trials for MDS explained in plain language.
Never miss a new study
Get alerted when new MDS trials appear
Sign up with your email to follow new studies for MDS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New weapon targets stubborn blood cancer cells
Disease control OngoingThis study is testing an experimental drug called vibecotamab for patients with two types of blood cancers (AML and MDS) that haven't responded fully to standard treatments or show lingering cancer cells. The trial aims to see if vibecotamab can eliminate these remaining cancer c…
Matched conditions: MDS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Blood cancer treatment showdown: two drug combo vs. single therapy
Disease control OngoingThis study is looking at which treatment works better for people with higher-risk forms of two blood disorders called MDS and CMML. Researchers are comparing a two-drug combination (venetoclax plus HMAs) against just the HMAs drug alone. They're reviewing medical records of 224 p…
Matched conditions: MDS
Sponsor: Guangdong Provincial People's Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for rare blood cancers: drug trial aims to shrink spleens and ease suffering
Disease control OngoingThis study is testing if the drug fedratinib is effective and safe for people with rare, hard-to-treat blood cancers. It will involve about 25 adults with specific conditions like MDS/MPN or chronic neutrophilic leukemia. The main goal is to see if the drug can control the diseas…
Matched conditions: MDS
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New attack plan for blood Cancer's comeback
Disease control OngoingThis study is testing a combination of two drugs (venetoclax and azacitidine) along with an infusion of immune cells from the original stem cell donor. It is for adults whose myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) has come back after a stem cell transplant…
Matched conditions: MDS
Phase: PHASE1, PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC